Who are 23vPPV+TIV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infanrix IPV, H-VA dual therapy, Boostrix®-IPV combination vaccine, Infanrix-IPV/Hib, hepatitis A vaccine, DTaP, PCV10, Infanrix TM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/23vppv-tiv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

23vPPV+TIV — Competitive Intelligence Brief

23vPPV+TIV (23vPPV+TIV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology / Infectious Disease.

marketed Combination vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

23vPPV+TIV (23vPPV+TIV) — Jiangsu Province Centers for Disease Control and Prevention. A combined pneumococcal and influenza vaccine that stimulates immune responses against 23 serotypes of Streptococcus pneumoniae and seasonal influenza virus strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
23vPPV+TIV TARGET	23vPPV+TIV	Jiangsu Province Centers for Disease Control and Prevention	marketed	Combination vaccine
Infanrix IPV	Infanrix IPV	GlaxoSmithKline	marketed	combination vaccine
H-VA dual therapy	H-VA dual therapy	The First Affiliated Hospital of Nanchang University	marketed	Combination vaccine
Boostrix®-IPV combination vaccine	Boostrix®-IPV combination vaccine	University of Oxford	marketed	combination vaccine
Infanrix-IPV/Hib	Infanrix-IPV/Hib	GlaxoSmithKline	marketed	combination vaccine
hepatitis A vaccine, DTaP, PCV10	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine
Infanrix TM	Infanrix TM	GlaxoSmithKline	marketed	Inactivated combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

GlaxoSmithKline · 22 drugs in this class
Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
Serum Institute of India Pvt. Ltd. · 3 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Sanofi · 3 drugs in this class
PT Bio Farma · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 23vPPV+TIV — Competitive Intelligence Brief. https://druglandscape.com/ci/23vppv-tiv. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab